Understanding how anesthetics work in the brain with the Salipro® platform - congrats to Ryan Hibbs and collaborators for publishing Salipro-GABA receptor structures in Nature. The study reveals mechanisms of anesthetics and psychoactive drugs binding to GABA receptors, opening up new ways to design novel and improved compounds. Salipro® and cryoEM for Structure Based Drug Design.
J. J. Kim, et al., Shared structural mechanisms of general anaesthetics and benzodiazepines. Nature (2020).
Salipro Biotech enters multi-target agreement with additional Top10 pharma company to advance programs using the Salipro® platform on challenging drug targets selected by the pharmaceutical partner.
Meet us at Oxford Global Conferences’s Biologics Series 2020: Virtual on August 27-28!
Our CSO, Robin Löving, will be discussing how you can use the Salipro platform for antibody and peptide discovery against challenging membrane proteins, such as GPCRs, ion channels and transporters.
You can also stop by our poster to chat with Anne-Sophie Tournillon, Scientist, or Maria Lisa Knudsen, PhD, Business Development.
Stuck in detergent, but alive in Salipro® - congrats to Christian Löw and colleagues at EMBL and Weizman Institute of Science for their recent publication in Angewandte Chemie, gaining a deeper understanding of drug transport and the full conformational spectrum of a peptide transporter in a Salipro® environment:
Salipro Biotech is looking forward to meeting with partners at the BIO International Convention in this year’s digital format. Collaboration is more important than ever, and we at Salipro Biotech are committed to combating unmet medical needs.
Antibiotic resistance in bacteria: New research out using Salipro® and DARPin®. Congrats to the Ben Luisi lab at the University of Cambridge for solving the high-resolution cryoEM structure of a bacterial multidrug transporter and its allosteric modulation.
Salipro Biotech is looking forward to meeting with partners at the COVID-19 Virtual Partnering Event and accelerating the discovery of new therapeutics against COVID-19.
The Salipro platform enables the development of drugs against full-length SARS-CoV-2 (S, M or E) or host (ACE2, immune signaling receptors, etc.) membrane proteins.
Salipro® and snake venom enabled researchers at UT Southwestern Medical Center to solve a high-resolution structure of the AChR muscle protein. Find out more about lipids, toxins and the permeation pathway in the recent publication by Ryan Hibbs and colleagues: Link to publication
Salipro Biotech and Bicycle Therapeutics jointly announce results from their collaboration on a wild-type GPCR drug target. Results have just been published in Frontiers in Bioengineering and Biotechnology: “DirectMX – One-Step Reconstitution of Membrane Proteins From Crude Cell Membranes Into Salipro Nanoparticles”.
Link to article: https://www.frontiersin.org/articles/10.3389/fbioe.2020.00215/full
Salipro Biotech's Maria Lisa Knudsen pitches at SwedenBIO's Shark Tank, as part of their executive dinner event. Two sharks, Carolin Wiken at Paues Åberg Communications and Carl Kilander at HealthCap, decided to "invest" in us, meaning we will be receiving coaching from them.